This article is more than 5 years old. Information may no longer be current.
Anti-VEGF results maintained at 1 year in COPERNICUS study
ORLANDO, Fla. — Less frequent dosing was needed and efficacy was maintained to week 52 in eyes treated with VEGF Trap-Eye, a speaker said here, reporting the 1-year results of the phase 3 COPERNICUS study.
"Significantly, events associated with disease progression ... were more frequent in the sham group," Julia A. Haller, MD, said at the American Academy of Ophthalmology meeting.
The COPERNICUS study is a randomized, double-masked controlled phase 3 trial in which one arm of patients with central retinal vein occlusion was treated with a 2-mg dose of VEGF Trap-Eye (aflibercept ophthalmic solution, Regeneron Pharmaceuticals, Bayer HealthCare) every 4 weeks for 24 weeks before being switched to an as-needed regimen. A second arm of patients was treated with sham therapy and then switched to as-needed dosing of aflibercept.
One-year results were similar to results reported at 24 weeks, in that mean change in best corrected visual acuity at week 52 in the aflibercept group was within one letter of outcomes reported for the same group at week 24.
- Disclosure: Dr. Haller is a consultant for or has financial interest in Allergan, Genentech, OptiMedica and ThromboGenics.